Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fatty liver gene hunt: could your DNA raise your risk?

NCT ID NCT07330830

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de la Guadeloupe Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is looking at a specific gene, PNPLA3, in 600 adults with a type of fatty liver disease called MASLD. Participants are from Guadeloupe, French Guiana, and Réunion Island. Researchers want to see how common certain gene variants are and if they are linked to more severe liver problems. This is an observational study, not a treatment trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help identify genetic factors that make some people more likely to develop severe liver disease, potentially guiding future prevention or treatment strategies.
What could go wrong
This is an observational study that only looks at gene patterns, not testing a treatment. It may not lead directly to any new therapy, and results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Prospective longitudinal multicentric study

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

IInclusion Criteria -Adult patients (≥18 years old) seen in consultation or hospitalized in the Hepato-Gastroenterology Departments of the University Hospitals of Guadeloupe, French Guiana, and Réunion Island, with a diagnosis of MASLD. MASLD is defined as evidence of hepatic steatosis associated with overweight/obesity, type 2 diabetes, or metabolic syndrome according to ATP III (2005) criteria. * Patients affiliated with, or beneficiaries of, a social security scheme. * Free, informed, and written consent obtained from the participant and signed by both the participant and the investigator (no later than the day of inclusion and prior to any procedure required by the study). Exclusion Criteria: * Patients under 18 years of age. * Patients unable to provide informed consent; so-called vulnerable populations (individuals under guardianship, judicial protection, etc.). * Presence of another cause of chronic liver disease, including: Viral hepatitis (B, C, or E) Primary biliary cholangitis or primary sclerosing cholangitis Autoimmune hepatitis Wilson's disease Hemochromatosis Alpha-1 antitrypsin deficiency Alcoholic liver disease, or daily alcohol consumption \>30 g/day for men or \>20 g/day for women -Pregnant women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Masld/mash (metabolic dysfunction-associated steatotic liver disease / metabolic dysfunction-associated steatohepatitis) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Masld/mash (metabolic dysfunction-associated steatotic liver disease / metabolic dysfunction-associated steatohepatitis)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de la Guadeloupe

    RECRUITING

    Pointe-à-Pitre, 97159, Guadeloupe

  • Centre Hospitalier Universitaire de la Guyane

    NOT_YET_RECRUITING

    Cayenne, 97306, French Guiana

  • Centre Hospitalier Universitaire de la Réunion

    NOT_YET_RECRUITING

    Saint-Denis, 97400, Reunion

More trials for these conditions

Other studies related to the condition(s) this trial covers.